On August 27, 2020 Bayer reported that The Chinese National Medical Products Administration (NMPA) has approved Xofigo (radium-223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases (Press release, Bayer, AUG 27, 2020, View Source,and%20no%20known%20visceral%20metastases. [SID1234564101]). The drug is already approved in more than 50 countries worldwide, including the U.S., the EU and Japan.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"With the aging of population, the incidence of prostate cancer has increased rapidly in China in recent years. Metastatic castration-resistant prostate cancer (mCRPC) is a form of cancer that has spread beyond the prostate and is resistant to medical or surgical treatments that lower testosterone," said Prof. Ye Dingwei, head of China Anti-Cancer Association-Genitourinary Cancer Committee. "Approximately 90% of patients with metastatic prostate cancer show evidence of bone metastases. Bone metastases can lead to an increase in frequency of skeletal events and have been shown to be the main cause of morbidity and death in patients with CRPC."
Xofigo is the only approved Targeted Alpha Therapy that has demonstrated improvement in overall survival (OS) and delay in time to first symptomatic skeletal event (SSE) compared to placebo in men with castration-resistant prostate cancer and symptomatic bone metastasis, as shown in the pivotal Phase III ALSYMPCA trial. The approval of Xofigo in China is based on the ALSYMPCA data as well as the Phase III 15397 trial operated in Asia.
"With our globally growing prostate cancer portfolio, we are pleased that Xofigo with its distinct mode of action is now available for patients in China," said Scott Z. Fields, M.D., senior vice president and head of Oncology Development of Bayer AG’s Pharmaceutical Division. "We remain committed to bringing additional therapeutic options to the increasing number of men living with prostate cancer in China to address their unmet medical needs."
About Xofigo (radium-223 dichloride) Radium-223 dichloride (radium-223) is a Targeted Alpha Therapy. It selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha particles leads to a high frequency of double-strand DNA breaks in adjacent tumor cells, resulting in a potent cytotoxic effect. The alpha particle range from radium-223 is less than 100 micrometers, which minimizes damage to the surrounding normal tissue.
ALSYMPCA Trial Design
The ALSYMPCA trial was a Phase III, randomized, double-blind, placebo-controlled international study of Xofigo with best standard of care vs. placebo with best standard of care in symptomatic castration-resistant prostate cancer (CRPC) patients with bone metastases. Interim and updated analyses of the trial showed Xofigo significantly improved overall survival.
About Oncology at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.